ImmunoPrecise Antibodies Ltd. acquires all remaining shares of ModiQuest Research BV for an aggregate price of C$11,200,000 making them an innovative, integrated antibody solution company that is focused on the next generation of technology behind therapeutic antibody discovery.
This creates a single source provider of services across the full antibody discovery value chain, such as an increased variety of therapeutically-focused methods of immunization and antigen design. This will include several highly effective methods of genetic immunization with multiplexed screening, B-cell screening and sorting technologies, efficient antibody expression, stable cell line development, and lead selection, optimization and characterization.
“Our acquisition of ModiQuest confirms our commitment to excellence as a CRO focused on the next generation of antibody discovery,” says Jennifer Bath, CEO of ImmunoPrecise. “Utilizing our teams’ extensive experience, combined with ModiQuest’s proprietary technologies, will further reduce timelines and enhance our unique capability to generate therapeutic antibodies with the highest probability of clinical success, as ImmunoPrecise continues to bring all related, core activities within one company. The acquisition is immediately accretive and will have a positive impact on consolidated revenues and earnings in the near future.”
The acquisition will build upon ImmunoPrecise’s existing antibody discovery technologies and will increase the probability of discovering therapeutically-relevant antibodies, which will transpire to greater success in the clinic.
ImmunoPrecise operates state of the art laboratory facilities located at the Vancouver Island Technology Park in Victoria, British Columbia which house its tissue culture and molecular facilities as well as an animal care unit. They are a member of the Canadian Council for Animal Care and are in association with U-Protein Express B.V. subsidiary laboratory operation in Life Science Incubator, Utrecht Science Park, Utrecht, the Netherlands.
The company offers customers the development of wild-type and humanized mouse and rat monoclonal antibodies and recombinant rabbit monoclonal antibodies against a wide spectrum of antigens, as well as polyclonal antibodies, immunologically-based assays, recombinant protein manufacturing, and advanced solutions to challenges faced by clients in antibody-related research and development. In addition, cryopreservation services are provided for the storage of valuable biological materials including hybridoma clones, plasmid constructs, and cell lines. The antibodies produced by ImmunoPrecise target a wide variety of therapeutic, diagnostic and research applications.